REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Active transport is the movement of a substance across a membrane against its concentration gradient. This is usually to accumulate high concentrations of molecules that a cell needs, such as glucose or amino acids. If the process uses chemical energy, such as adenosine triphosphate (ATP), it is called primary active transport. Membrane transport proteins that are driven directly by the hydrolysis of ATP are referred to as ATPase pumps. These types of pumps direct the exergonic hydrolysis of ATP to the unfavorable movement of molecules against their concentration gradient. Examples of ATPase pumps include P-type ATPase's, V-type ATPases, F-type ATPases, and ABC binding cassettes. Secondary active transport involves the use of an electrochemical gradient, and does not use energy produced in the cell. Secondary active transport commonly uses types of carrier proteins, typically symporters and antiporters. Symporter proteins couple the transport of one molecule down its concentration gradient to the transport of another molecule against its concentration gradient, and both molecules diffuse in the same direction. Antiporter proteins transport one molecule down its concentration gradient to transport another molecule against its concentration gradient, but the molecules diffuse in opposite directions. As symporters and antiporters are involved in coupling the transport of two molecules, they are commonly referred to as cotransporters.
Databases are essential for bioinformatics research and applications. Databases exist for many different information types, including DNA and protein sequences, molecular structures, phenotypes and biodiversity. Databases can contain both empirical data (obtained directly from experiments) and predicted data (obtained from analysis of existing data). They may be specific to a particular organism, pathway or molecule of interest. Alternatively, they can incorporate data compiled from multiple other databases. Databases can have different formats, access mechanisms, and be public or private. Some of the most commonly used databases are listed below: Used in biological sequence analysis: Genbank, UniProt Used in structure analysis: Protein Data Bank (PDB) Used in finding Protein Families and Motif Finding: InterPro, Pfam Used for Next Generation Sequencing: Sequence Read Archive Used in Network Analysis: Metabolic Pathway Databases (KEGG, BioCyc), Interaction Analysis Databases, Functional Networks Used in design of synthetic genetic circuits: GenoCAD
An estimated 160 TBq (about 250 kg) of technetium-99 was released into the environment by atmospheric nuclear tests. The amount of technetium-99 from civilian nuclear power released into the environment up to 1986 is estimated to be on the order of 1000 TBq (about 1600 kg), primarily by outdated methods of nuclear fuel reprocessing; most of this was discharged into the sea. In recent years, reprocessing methods have improved to reduce emissions, but the Sellafield plant, which operated until 2022, released an estimated 550 TBq (about 900 kg) from 1995–1999 into the Irish Sea; afterward the amount was limited by regulation to 90 TBq (about 140 kg) per year.
== Medical uses == In the United States, sotagliflozin is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure; or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
Sources: en.wikipedia.org
=== Aesthetic medicine === Platelet-rich plasma therapy is a minimally invasive procedure that may be used in aesthetic medicine to treat skin conditions such as the removal of wrinkles, the reduction of lines, and improvement of blemishes, and hair loss. Concentrated PRP solution is injected into the treatment area to target damaged cells and tissues. The growth factors and proteins in PRP aid in rejuvenating the skin, and improving the condition of the scalp stimulating hair growth.
The French Second Republic (French: Deuxième république française or La IIe République), officially the French Republic (République française), was the second republican formation of the government of France. The republic existed from 1848, when the monarchy fell, until its dissolution only four years later in 1852 upon the proclamation of the Second French Empire. Following the final defeat of Napoleon Bonaparte at the Battle of Waterloo, in June 1815, France had been reconstituted into a monarchy known as the Bourbon Restoration. After a brief period of revolutionary turmoil in 1830, royal power was again secured in the "July Monarchy", governed under principles of moderate conservatism and improved relations with the United Kingdom. In 1848, Europe erupted into a mass revolutionary wave in which many citizens challenged their royal leaders. Much of it was led by France in the February Revolution, overthrowing King Louis-Philippe. Radical and liberal factions of the population convened the French Second Republic in 1848. Attempting to restore the First French Republic's values on human rights and constitutional government, they adopted the motto of the First Republic; Liberté, Égalité, Fraternité. The republic was plagued with tribalist tendencies of its leading factions: royalists, proto-socialists, liberals, and conservatives. In this environment, Napoleon's nephew, Louis-Napoléon Bonaparte, established himself as a popular anti-establishment figure and was elected president in 1848.
Further action is planned for Saturday, the day of the FA Cup Final, and on Friday by members of RMT. A huge wildfire covering 30 mi2 (78 km2), possibly the largest ever seen in the UK, is brought under control by the Scottish Fire and Rescue Service at Cannich in the Highlands.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.